Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
31 results about "Serotonin transport" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The directed movement of serotonin into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Serotonin (5-hydroxytryptamine) is a monoamine neurotransmitter occurring in the peripheral and central nervous systems. [GOC:ai]
Methods and compositions for predicting compliance with an antidepressant treatment regimen
InactiveUS20050165115A1Reduce complianceImprove complianceBiocideOrganic active ingredientsGenotype determinationSerotonin transport
Methods and compositions are provided for predicting whether a subject will comply with an antidepressant treatment regimen. In practicing the subject methods, a subject's serotonin transporter gene-linked polymorphic region (5HTTLPR) is genotyped. Based on the identified genotype, a particular antidepressant treatment regimen suitable for the patient is determined. Also provided are kits for practicing the subject methods.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Tetrahydroisoquinoline compounds
Certain tetrahydroisoquinoline compounds are histamine H3 receptor and serotonin transporter modulators useful in the treatment of histamine H3 receptor- and serotonin-mediated diseases.
Owner:JANSSEN PHARMA NV
Organic compounds
ActiveUS20170183350A1To promote metabolismImproves in vitro hepatic microsome stabilityOrganic active ingredientsNervous disorderDisease5-HT3 receptor
The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and / or pathways involving dopamine D1 / D2 receptor signaling systems, and / or the treatment of residual symptoms.
Owner:INTRA CELLULAR THERAPIES INC
Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity
ActiveUS9708322B2High activityPromote disseminationOrganic active ingredientsOrganic chemistryQuinoxalineDisease
![Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/98a75e2d-75e1-48ce-aec0-985d9e07e9a0/US09708322-20170718-C00001.png "Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity")
![Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/98a75e2d-75e1-48ce-aec0-985d9e07e9a0/US09708322-20170718-C00002.png "Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity")
![Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/98a75e2d-75e1-48ce-aec0-985d9e07e9a0/US09708322-20170718-C00003.png "Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity")
Owner:INTRA CELLULAR THERAPIES INC
Organic compounds
The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and / or pathways involving dopamine D2 receptor signaling systems.
Owner:INTRA CELLULAR THERAPIES INC
Organic compounds
ActiveUS10077267B2Similar biological activityTo promote metabolismOrganic active ingredientsIsotope introduction to heterocyclic compoundsDisease5-HT4 receptor
Owner:INTRA CELLULAR THERAPIES INC
Serotonin transporter gene and treament of alcoholism
ActiveUS20110112159A1Physical improvementImproving psychological sequelaOrganic active ingredientsBiocideDiseaseAlcoholisms
The gene responsible for encoding SERT has a functional polymorphism at the 5′-regulatory promoter region, which results in two forms, long (L) and short (S). The LL-genotype is hypothesized to play a key role in the early onset of alcohol use. The present invention discloses the differences in treatment and diagnosis based on the L or short genotypes as well as on a single nucleotide polymorphism of the SERT gene, the 3′ UTR SNP rs 1042173. The present invention demonstrates the efficacy of using the drug ondansetron and similar drugs for treatment based on variations in the polymorphisms of the SERT gene as well as methods for diagnosing susceptibility to abuse of alcohol and other addiction-related diseases and disorders.
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND
METHOD FOR ANALYZING STRUCTURE AND PURITY OF SEROTONIN TRANSPORTER IMAGING AGENT [123I] ADAM AND PRECURSOR SnADAM
InactiveUS20100112706A1Guaranteed reliabilityGuarantee stabilityParticle separator tubesComponent separationImaging agentSerotonin transport
An analytical technique for determining the structures of serotonin transporter (SERT) imaging agent [123I] ADAM and its precursor, SnADAM by using a high-performance liquid chromatography tandem mass spectrometer (LC-MS / MS) is provided. An analytical technique for determining the purity of SnADAM by using a high-performance liquid chromatograph (HPLC) is also provided.
![METHOD FOR ANALYZING STRUCTURE AND PURITY OF SEROTONIN TRANSPORTER IMAGING AGENT [123I] ADAM AND PRECURSOR SnADAM](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/61107c5b-ba0a-415c-9754-16ba2eb265da/US20100112706A1-20100506-D00000.png "METHOD FOR ANALYZING STRUCTURE AND PURITY OF SEROTONIN TRANSPORTER IMAGING AGENT [123I] ADAM AND PRECURSOR SnADAM")
![METHOD FOR ANALYZING STRUCTURE AND PURITY OF SEROTONIN TRANSPORTER IMAGING AGENT [123I] ADAM AND PRECURSOR SnADAM](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/61107c5b-ba0a-415c-9754-16ba2eb265da/US20100112706A1-20100506-D00001.png "METHOD FOR ANALYZING STRUCTURE AND PURITY OF SEROTONIN TRANSPORTER IMAGING AGENT [123I] ADAM AND PRECURSOR SnADAM")
![METHOD FOR ANALYZING STRUCTURE AND PURITY OF SEROTONIN TRANSPORTER IMAGING AGENT [123I] ADAM AND PRECURSOR SnADAM](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/61107c5b-ba0a-415c-9754-16ba2eb265da/US20100112706A1-20100506-D00002.png "METHOD FOR ANALYZING STRUCTURE AND PURITY OF SEROTONIN TRANSPORTER IMAGING AGENT [123I] ADAM AND PRECURSOR SnADAM")
Owner:INST NUCLEAR ENERGY RES ROCAEC
Boat tropanes
InactiveUS7105678B2Useful in therapyRadioactive preparation carriersRadiation therapyRheniumEnantiomer
Radiopharmaceutical compounds are disclosed. A tropane compound is linked through the N atom at the 8-position to a chelating ligand capable of complexing technetium or rhenium to produce a neutral labeled complex that selectively binds to the dopamine transporter over the serotonin transporter with a ratio of 10 or more. These compounds can be prepared as separate diastereoisomers as well as a mixture of diastereoisomers. Also disclosed are radiopharmaceutical kits for preparing the labeled radiopharmaceutical compounds.
Owner:ORGANIX +2
Organic compounds
ActiveUS11376249B2Enhanced signalPotent activityNervous disorderAnaestheticsDiseasePharmaceutical medicine
Owner:INTRA CELLULAR THERAPIES INC
Interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression
InactiveUS20070224599A1Reduce and prevent manifestationSusceptible to effectMicrobiological testing/measurementLife eventsSerotonin transport
People with the SS variant of the human serotonin transporter gene are more susceptible to episodes of major depression when faced with mildly threatening life events than people with the SL or LL variants. Methods for identifying and treating such patients are provided.
Owner:VIRGINIA COMMONWEALTH UNIV
Method for analyzing structure and purity of serotonin transporter imaging agent [123 I] ADAM and precursor SnADAM
InactiveUS8153441B2Guaranteed reliabilityGuarantee stabilityParticle separator tubesComponent separationImaging agentSerotonin transport
![Method for analyzing structure and purity of serotonin transporter imaging agent [<sup>123 </sup>I] ADAM and precursor SnADAM](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/3e7df8c7-e1ee-49e7-aa9d-bca56f822be3/US08153441-20120410-D00000.png "Method for analyzing structure and purity of serotonin transporter imaging agent [<sup>123 </sup>I] ADAM and precursor SnADAM")
![Method for analyzing structure and purity of serotonin transporter imaging agent [<sup>123 </sup>I] ADAM and precursor SnADAM](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/3e7df8c7-e1ee-49e7-aa9d-bca56f822be3/US08153441-20120410-D00001.png "Method for analyzing structure and purity of serotonin transporter imaging agent [<sup>123 </sup>I] ADAM and precursor SnADAM")
![Method for analyzing structure and purity of serotonin transporter imaging agent [<sup>123 </sup>I] ADAM and precursor SnADAM](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/3e7df8c7-e1ee-49e7-aa9d-bca56f822be3/US08153441-20120410-D00002.png "Method for analyzing structure and purity of serotonin transporter imaging agent [<sup>123 </sup>I] ADAM and precursor SnADAM")
Owner:INST NUCLEAR ENERGY RES ROCAEC
Combination therapy related to serotonin dual action compounds
The present invention relates to combination therapies and pharmaceutical compositions comprising a combination of 5-hydroxytryptophan and a serotonin reuptake inhibitor that binds to an ailosteric site of the serotonin transporter. The present invention further provides a pharmaceutical composition comprising (i) 5-hydroxytryptophan in an amount ranging from about 1 mg to about 75 mg; and (ii) a serotonin reuptake inhibitor that binds to an allosteric site of the serotonin transporter.
Owner:H LUNDBECK AS
Pyrovalerone Analogues and Therapeutic Uses Thereof
New compounds that bind to monoamine transporters are described. The compounds of the present invention can be racemic or pure R— or S-enantiomers. Certain preferred compounds of the present invention have a high selectively dopamine transporter versus the serotonin transporter. Preferred monoamine transporters for the practice of the present invention include the dopamine transporter, the serotonin transporter and the norepinephrine transporter.
Owner:ORGANIX +1
Organic compounds
PendingUS20210008065A1Inhibit the serotonin re-uptake transporterModulate dopaminergic protein phosphorylationOrganic active ingredientsIsotope introduction to heterocyclic compoundsDiseasePharmaceutical drug
The invention relates to particular substituted deuterated heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and / or pathways involving dopamine D1 / D2 receptor signaling systems, and / or the treatment of residual symptoms.
Owner:INTRA CELLULAR THERAPIES INC
Organic compounds
PendingUS20200392135A1Avoid side effectsSignificant pharmacologic activityOrganic active ingredientsNervous disorderDiseasePharmaceutical drug
The invention relates to particular substituted fluorinated heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and / or pathways involving dopamine D1 / D2 receptor signaling systems, and / or the treatment of residual symptoms.
Owner:INTRA CELLULAR THERAPIES INC
Organic compounds
PendingUS20210009592A1Strong therapeutic activitySide effect can be reduced and minimizedOrganic active ingredientsIsotope introduction to heterocyclic compoundsDiseasePharmaceutical medicine
The invention relates to particular deuterated substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and / or the μ-opioid receptor.
Owner:INTRA CELLULAR THERAPIES INC
Organic compounds
ActiveUS20210145829A1Potent activityEnhanced signalNervous disorderAnaestheticsDiseasePharmaceutical medicine
The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and / or the μ-opioid receptor.
Owner:INTRA CELLULAR THERAPIES INC
Tropane analogs and methods for inhibition of monoamine transport
New tropane analogs that bind to monoamine transporters are described, particularly, 8-aza, 8carbo and 8-oxo tropanes having 6- or 7-hydroxyl or ketone substituents. The compounds of the present invention can be racemic, pure R-enantiomers, or pure S-enantiomers. Certain preferred compounds of the present invention have a high selectivity for the DAT versus the SERT. Also described are pharmaceutical therapeutic compositions comprising the compounds formulated in a pharmaceutically acceptable carrier and a method for inhibiting 5-hydroxy-tryptamine reuptake of a monoamine transporter by contacting the monoamine transporter with a 5-hydroxytryptamine reuptake inhibiting amount of a compound of the present invention. Preferred monoamine transporters for the practice of the present invention include the dopamine transporter, the serotonin transporter and the norepinephrine transporter.
Owner:ORGANIX
Bridged aryl piperazines derivatives useful for the treatment of cns, gi-urinary and reproductive disorders
The present invention is directed to bridged aryl piperazine derivatives, pharmaceutical compositions containing them and their use in the treatment of depression and related disorders. The compounds of the present invention are serotonin transport inhibitors and / or modulators of 5HT1A.
Owner:JANSSEN PHARMA NV
Method for examining long-term prognosis of acute coronary syndrome and diagnostic kit
InactiveUS20200377947A1Accurately determineClinical useMicrobiological testing/measurementCoronary arteriesSerotonin transport
A diagnostic method according to an embodiment of the present invention is to determine prognosis, such as recurrence and death, which commonly occurs after acute coronary syndrome. A method of determining long-term prognosis of acute coronary syndrome includes analyzing anxiety and serotonin transporter gene polymorphism associated therewith. The method is capable of determining the risk of incidence of major adverse cardiac events including recurrence and / or death after acute coronary syndrome.
Owner:IND FOUND OF CHONNAM NAT UNIV
Diphenyl ether derivatives and their use for imaging serotonin transporters
InactiveUS20060083680A1Organic compound preparationRadioactive preparation carriersDiseaseDiphenyl ether
This invention relates to diphenyl ether derivatives and their use in imaging of Serotonin Transporters (SERTS). The present invention also provides diagnostic compositions comprising the compounds of the present invention, and a pharmaceutically acceptable carrier or diluent. The invention further provides a method of imaging SERTS, comprising introducing into a patient a detectable quantity of a labeled compound of the present invention, or a pharmaceutically acceptable salt, ester, amide or prodrug thereof, allowing sufficient time for the labeled compound to associate with one or more SERTs, and detecting the labeled compound. The present invention can also be used to follow the progression of a disease associated with SERTs or a therapy that targets SERTs.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Assays for novel serotonin transporter (SERT) blockers
The serotonin transporter (SERT) is a target of various therapeutic agents used in the treatment of neurological and neurodegenerative disorders. The present invention provides novel forms of SERT that lacks high affinity recognition of specific serotonin reuptake inhibitors (SSRIs). The present invention therefore provides a novel target for use in screening and model development that can aid both the discovery of new medications and the discovery of novel pathways impacted in parallel with SERT blockade. Such novel targets can help identify new SSRI's with unique modifications and lead to discovery of pathways that secondarily support the therapeutic activity of these agents.
Owner:VANDERBILT UNIV
Method for radio-labeling serotonin transporter ligand, 123I-IADM
There is disclosed a method for using 123I to radiolabel SnADAM become an serotonin transporter radiotracer(123I -ADAM). At first, there is provided SnADAM solution via mixing SnADAM with ethanol. The SnADAM solution is shaken and further mixed with thin KI solution. The SnADAM solution is mixed with 123I-NH4I solution and H2O2 solution. The SnADAM-123I-NH4I—H2O2 mixture is kept still. Later, the SnADAM solution is mixed with NaHSO3 solution, and the mixture is shaken and further mixed with buffer solution of saturated Na2HPO4. The SnADAM solution is filled in an Accubond C8 column. The Accubond C8 column is washed with sterile water for injection to isolate non-reacting 123I ions. The Accubond C8 column is washed with ethanol, thus providing 123I-ADAM. The 123I-ADAM is blended in normal saline mixture. Millipore Millex GV is used to filter impurities and bacteria from the 123I-ADAM solution.
Owner:INST NUCLEAR ENERGY RES ROCAEC
Organic compounds
PendingUS20220048910A1Strong therapeutic activityHigh activityOrganic active ingredientsNervous disorderDiseasePharmaceutical drug
Please add the following heading and paragraph on a separate sheet, after the claims: The invention relates to particular substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and / or the μ-opioid receptor.
Owner:INTRA CELLULAR THERAPIES INC
Organic compound
Owner:INTRA CELLULAR THERAPIES INC
Combination therapy related to serotonin dual action compounds
InactiveCN101868233AOrganic active ingredientsNervous disorderDual actionSerotonin receptor inhibitors
Owner:H LUNDBECK AS
Organic compounds
PendingCN112088004AOrganic active ingredientsIsotope introduction to heterocyclic compoundsDiseasePharmaceutical drug
The invention relates to particular substituted deuterated heterocycle fused gamma- carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and / or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and / or pathways involving dopamine D1 / D2 receptor signaling systems, and / or the treatment of residual symptoms.
Owner:INTRA CELLULAR THERAPIES INC
Organic compounds
PendingUS20220296591A1Enhanced signalPotent activityNervous disorderAnaestheticsDiseasePharmaceutical medicine
Owner:INTRA CELLULAR THERAPIES INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com